Yiannis Kallis1, Natalie Phillips2, Alan Steel3, Harry Kaltsidis4, Panagiotis Vlavianos5, Nagy Habib6, David Westaby7. 1. HPB Unit/Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. yiannis.kallis@nhs.net. 2. HPB Unit/Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. natalie.phillips@imperial.nhs.uk. 3. Department of Gastroenterology, Chelsea and Westminster Hospital NHS Trust, London, UK. alan.steel@chelwest.nhs.uk. 4. HPB Unit/Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. harry.kaltsidis@nhs.net. 5. HPB Unit/Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. panagiotis.vlavianos@imperial.nhs.uk. 6. Academic Department of Surgery, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. nagy.habib@imperial.nhs.uk. 7. HPB Unit/Department of Gastroenterology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, Du Cane Road, London, W12 0HS, UK. david.westaby@imperial.nhs.uk.
Abstract
BACKGROUND: Pancreatic carcinoma is often inoperable, carries a poor prognosis, and is commonly complicated by malignant biliary obstruction. Phase I/II studies have demonstrated good safety and early stent patency using endoscopic biliary radiofrequency ablation (RFA) as an adjunct to self-expanding metal stent (SEMS) insertion for biliary decompression. AIM: To analyze the clinical efficacy of endobiliary RFA. METHODS: Retrospective case-control analysis was carried out for 23 patients with surgically unresectable pancreatic carcinoma and malignant biliary obstruction undergoing endoscopic RFA and SEMS insertion and 46 controls (SEMS insertion alone) in a single tertiary care center. Controls were stringently matched for age, sex, metastases, ASA/comorbidities. Survival, morbidity, and stent patency rates were assessed. RESULTS: RFA and control groups were closely matched-ASA 2.35 ± 0.65 versus 2.54 ± 0.50, p = 0.086; metastases 9/23 (39.1%) versus 18/46 (39.1%), p = 0.800; chemotherapy 16/23 (69.6%) versus 24/46 (52.2%), p = 0.203. Median survival in RFA group was 226 days (IQR 140-526 days) versus 123.5 days (IQR 44-328 days) in controls (p = 0.010). RFA was independently predictive of survival at 90 days (OR 21.07, 95% CI 1.45-306.64, p = 0.026) and 180 days (OR 4.48, 95% CI 1.04-19.30, p = 0.044) in multivariate analysis. SEMS patency rates were equivalent in both groups. RFA was well tolerated with minimal side effects. CONCLUSIONS: Endoscopic RFA is a safe and efficacious adjunctive treatment in patients with advanced pancreatic malignancy and biliary obstruction and may confer early survival benefit. Randomized prospective clinical trials of this new modality are mandated.
BACKGROUND:Pancreatic carcinoma is often inoperable, carries a poor prognosis, and is commonly complicated by malignant biliary obstruction. Phase I/II studies have demonstrated good safety and early stent patency using endoscopic biliary radiofrequency ablation (RFA) as an adjunct to self-expanding metal stent (SEMS) insertion for biliary decompression. AIM: To analyze the clinical efficacy of endobiliary RFA. METHODS: Retrospective case-control analysis was carried out for 23 patients with surgically unresectable pancreatic carcinoma and malignant biliary obstruction undergoing endoscopic RFA and SEMS insertion and 46 controls (SEMS insertion alone) in a single tertiary care center. Controls were stringently matched for age, sex, metastases, ASA/comorbidities. Survival, morbidity, and stent patency rates were assessed. RESULTS: RFA and control groups were closely matched-ASA 2.35 ± 0.65 versus 2.54 ± 0.50, p = 0.086; metastases 9/23 (39.1%) versus 18/46 (39.1%), p = 0.800; chemotherapy 16/23 (69.6%) versus 24/46 (52.2%), p = 0.203. Median survival in RFA group was 226 days (IQR 140-526 days) versus 123.5 days (IQR 44-328 days) in controls (p = 0.010). RFA was independently predictive of survival at 90 days (OR 21.07, 95% CI 1.45-306.64, p = 0.026) and 180 days (OR 4.48, 95% CI 1.04-19.30, p = 0.044) in multivariate analysis. SEMS patency rates were equivalent in both groups. RFA was well tolerated with minimal side effects. CONCLUSIONS: Endoscopic RFA is a safe and efficacious adjunctive treatment in patients with advanced pancreatic malignancy and biliary obstruction and may confer early survival benefit. Randomized prospective clinical trials of this new modality are mandated.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Gregory A Coté; Nitin Kumar; Michael Ansstas; Steven A Edmundowicz; Sreenivasa Jonnalagadda; Daniel K Mullady; Riad R Azar Journal: Gastrointest Endosc Date: 2010-07-13 Impact factor: 9.427
Authors: Andrea Oliver Tal; Johannes Vermehren; Mireen Friedrich-Rust; Jörg Bojunga; Christoph Sarrazin; Stefan Zeuzem; Jörg Trojan; Jörg Gerhard Albert Journal: World J Gastrointest Endosc Date: 2014-01-16
Authors: Werner Dolak; Florian Schreiber; Hubert Schwaighofer; Michael Gschwantler; Wolfgang Plieschnegger; Alexander Ziachehabi; Andreas Mayer; Ludwig Kramer; Andreas Kopecky; Christiane Schrutka-Kölbl; Gernot Wolkersdörfer; Christian Madl; Frieder Berr; Michael Trauner; Andreas Püspök Journal: Surg Endosc Date: 2013-10-03 Impact factor: 4.584
Authors: Reem Z Sharaiha; Nikola Natov; Kati S Glockenberg; Jessica Widmer; Monica Gaidhane; Michel Kahaleh Journal: Dig Dis Sci Date: 2014-07-18 Impact factor: 3.199
Authors: Martijn H M G M den Brok; Roger P M Sutmuller; Robbert van der Voort; Erik J Bennink; Carl G Figdor; Theo J M Ruers; Gosse J Adema Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Muhammad Nadeem Yousaf; Hamid Ehsan; Ahmad Muneeb; Ahsan Wahab; Muhammad K Sana; Karun Neupane; Fizah S Chaudhary Journal: Front Med (Lausanne) Date: 2021-02-11